News

At the forefront of PharmNovo's journey towards pioneering solutions in pain relief stands Jarkko Kalliomäki, our esteemed Chief Medical Officer since September 2022. With his profound knowledge and unwavering commitment, Jarkko brings a unique perspective to our mission.

As PharmNovo advances into phase II clinical studies with drug candidate PN6047, Chief Scientific Officer David Kendall plays a crucial role in the company’s success. With three decades of expertise bridging academia and industry, his visionary leadership and groundbreaking ideas are instrumental.

PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.

We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.

PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.

PharmNovo, currently at the clinical stage of pioneering a novel solution for neuropathic pain treatment, is pleased to announce the appointment of Alexander Dahlquist as the new CFO.